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Abstract. Breast cancer is the most common cancer and a significant cause of morbidity and mortality in the female 
population worldwide. The liver is the third most common metastatic site for invasive breast malignancy besides bones, 
lungs, and brain. Breast cancer has been linked with metachronous bone, endometrial, colon/rectal, connective tissue 
(sarcoma), leukemia, lung, ovary, or thyroid cancer. Studies have shown an increased risk of secondary malignancies in 
women treated for breast malignancy in connection to adjuvant treatment in certain cases.  
We present a case of a 71 -year -old woman who was diagnosed with breast cancer 20 years ago. The primary diagnosis 
was invasive lobular breast cancer localized in the left lower lateral quadrant. Micromorphological, histochemical and 
immunohistochemical analyses rendered diagnosis inconclusive due to lack of tissue so after 4 months rebiopsy was 
performed. Clinico-pathological correlation of the second biopsy was in favor of liver metastasis of partially hormone- 
dependent breast cancer. Immunohistochemistry was vital for the diagnosis  of  the liver biopsy, in particular GATA3 
positivity and vimentin negative staining which helped us exclude endometrial cancer metastasis which was diagnosed 
before the initial liver biopsy. GATA 3(+)/vimentin(-) panel proved to be superior to GCDFP-15 and mammaglobin in 
proving the breast origin of the secondary tumor deposit. 
Liver metastasis from primary breast cancer can in certain cases occur many years after the initial diagnosis which shows 
the importance and necessity for long- term follow-up of these patients, while considering the possibility of metachronous 
tumors as well. 
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Introduction 
Breast cancer is the most common cancer and a signifi-
cant cause of morbidity and mortality in the female pop-
ulation worldwide. In around 20% - 30% of cases distant 
metastases occur [1]. 
Breast cancer usually disseminates to bones, lungs, 
liver, and brain by hematogenous spread; the liver is the 
third most common metastatic site for invasive breast 
malignancy [2]. 
The status of estrogen receptor (ER), progesterone re-
ceptor (PR), and human epidermal growth factor receptor 
2 (HER-2) in primary and metastatic breast cancers was 
evaluated and links between ER, PR, and HER-2 with 
various localisations of breast cancer (including liver) 
were investigated. ER+ or PR+/HER-2- (luminal A) sub-
types were present in 75.0% of the cases [3]. 
A panel of immunohistochemical markers necessary 
for confirming the breast origin of the metastatic deposit 
consists of: GATA3, mammaglobin and gross cystic dis-
ease fluid protein 15 (GCDFP-15). In clinical practice, 
GATA3 immunohistochemistry stains a greater number 
of primary and secondary breast carcinomas than both 
mammaglobin and GCDFP-15 [4]. 
If the tumor reoccurs five or more years after the ini-
tial diagnosis, it would indicate a long -dormant period of 
undetectable metastases. Recent studies have focused on 
predicting the risk of late breast cancer recurrence by in-
vestigating clinical factors, subtypes, genes, and  immune 
status. In a recent study early to mid  recurrence was as-
sociated with more aggressive clinical progression and 
less favourable parameters (greater tumor diameter, more 
frequent lymph node metastases, higher tumor grades, 
later stages, and negative ER and PR hormone status) 
compared to survivors and the patients with late breast 
cancer recurrence [5]. 
Metastasising breast carcinomas need to be differen-
tiated from synchronous/metachronous gynecological 
malignant tumors with an estrogen receptor/cytokeratin 
7-positive (ER+/CK7+) and mammaglobin-positive im-
munohistochemical profile, which can be achieved by us-
ing GATA3 immunohistohemical stain which proved to 
be highly useful in diagnosing breast carcinomas, both 
primary and metastatic [6]. 
Here we report a case of a patient with breast cancer 
liver metastasis 20 years after primary diagnosis, which 
was confirmed on a liver biopsy by pathohistological and 
immunohistochemical analysis. 
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Materials and Methods 
Liver biopsy was formalin- fixed (10% neutral buffered 
formalin), processed, paraffin- embedded, and then 
stained using standard hematoxylin and eosin(H&E) 
stain. The specimen was also stained histochemically us-
ing alcian blue- periodic acid-Schiff (AB-PAS) staining 
method at pH 2.5. 
The tissue from the paraffin moulds was cut into 4 µm 
thick sections and placed on aptaca slides. In brief, 4 μm 
thick tissue sections were deparaffinized in xylene and 
rehydrated in a graded series of ethanol, and deionized 
water. Following adequate heat-induced antigen retrieval 
procedure, the endogenous peroxidase activity was 
quenched, and the slides were rinsed thoroughly with 
phosphate- buffered saline. The primary antibodies (Cy-
tokeratin  mouse clone AE1/AE3, mouse monoclonal 
CA125-clone M11, rabbit HER2-polyclonal, mouse 
monoclonal Estrogen receptor-clone 1D5, mouse mono-
clonal Progesteron receptor-clone PgR 636, and mouse 
monoclonal vimentin-clone V9 were applied and the 
slides were incubated in a water bath for one hour at room 
temperature. Appropriate positive and negative controls 
were included in every immunostaining procedure. For 
the visualization reaction, a standard immunoperoxidase 
detection system was applied according to the manufac-
turer’s instructions (DAKO LSAB2R system-HRP, 
Dako, Denmark), and diaminobenzidine was used as a 
chromogen. Slides were afterward counterstained with 
Mayer’s hematoxylin, dehydrated, and mounted.  
Using autostainer Ventana Benchmark GX tissue 
sections were stained with monoclonal ready to use 
antibodies GATA3-mouse clone L50-823, GCDFP-15 
(EP1582Y) Rabbit Monoclonal Antibody, and p16- 
CINtec. 
Case Report 
We present a case of a 71- year- old woman who was 
diagnosed with breast cancer 20 years ago. The primary 
diagnosis was invasive lobular breast cancer localized in 
the left lower lateral quadrant. Soon after primary diag-
nosis left mastectomy was performed, and the patient re-
ceived radiation therapy afterwards. During a detailed 
follow-up 3 years ago she was diagnosed with endome-
trial cancer and treated accordingly. During the time of 
the liver biopsy on scintigraphy, multiple tumor deposits 
were noted.  
Initially, the pathohistological examination of a liver 
biopsy sample showed the focal presence of dense infil-
trates of inflammatory and reactive cells predominantly 
with ovoid and irregular morphology, abundant and oc-
casionally eosinophile granular cytoplasm resembling 
histiocytes. Histochemical and immunohistochemical 
staining of these cells showed positivity for toluidine blue 
while it was negative on AB PAS, CK7, S100, CD 68, 
and mammaglobin. Additional immunohistochemical 
analyses weren't possible due to lack of tissue, so a re-
biopsy was suggested.  
After 4 months, the rebiopsy was performed which 
showed a marginal area of proliferative connective tissue 
with individual and small groups of discohesive cells 
(Figure 1.A, 1.B). The nuclei of these cells were localized 
marginally and mucins were not observed in the cyto-
plasm of individual cells (Figure 1.C). Immunohisto-
chemical staining showed CKAE1/E3 (Figure 1.E), 
GATA3 (Figure 2.A), ER positivity and Ca125 (Figure 
2.B, 2.E), GCDFP-15 (Figure 1.D), p16 (Figure 2.F), PR 
(Figure 2.C), HER2 (Figure 2.D), vimentin negative 
staining (Figure 1.F). 
Immunohistochemistry, micromorphology and clinico-
pathological correlation were in favor of  the liver metastasis 
of partially hormone dependent breast cancer (strong 
nuclear expression of estrogen receptors on most tumor cells 
and negative expression of progesteron receptors as well as 
HER 2 receptor negative staining). 
Discussion 
Breast cancer most frequently metastases to the lymph 
nodes, liver, bones, and lungs. Liver metastases from 
breast cancer may present asymptomatically or with di-
gestive tract system symptoms like bloating, ascites, pal-
pable abdominal mass, jaundice, or weight loss [1]. 
Breast cancer has been linked with metachronous 
bone, endometrial, colon/rectal, connective tissue (sar-
coma), leukemia, lung, ovary, or thyroid cancer. The 
most common second primary cancer in breast cancer pa-
tients was that of the opposite breast (23.9%), it was de-
tected on an average of 7 years after the first cancer was 
detected.  The risk of endometrial, thyroid, and ovarian 
cancer was higher than that of the general population [7]. 
Studies have shown an increased risk of secondary 
malignancies in women treated for breast malignancy in 
connection to adjuvant treatment in certain cases. Higher 
endometrial cancer incidence has been  observed in adju-
vant trials of tamoxifen [8]. Endometrial cancer was not 
entirely caused by tamoxifen but also influenced by pa-
rameters like reproductive and genetic factors, obesity, 
and in some cases unknown factors that could lead to es-
trogen excess [9]. Women in the postmenopausal period 
with symptoms  that arouse suspicion for endometrial hy-
perplasia or cancer and who are using tamoxifen should 
be evaluated in terms of therapy and diagnostics [10]. 
A majority of breast cancers (more than 90%) are di-
agnosed as no special type (NST) invasive carcinoma, 
which is characterized by tubule formation that resem-
bles adenocarcinoma, the main differential diagnosis of 
metastatic breast carcinoma in the liver is primary intra-
hepatic cholangiocarcinoma. Histologically, breast carci-
noma consists of atypical epithelial cells with lightly 
monomorphic or highly pleomorphic nuclei arranged in 
tubular, glandular, cribriform, or solid patterns [11]. In 
our case tumor cells had a discohesive pattern resembling 
lobular carcinoma unlike endometrial adenocarcinoma 
which has a glandular pattern. 
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Fig. 1 A. Well demarcated metastatic focus on liver needle biopsy (HE x100); B. Higher magnification shows a 
relatively uniform population of cells some with “signet ring” features (HE x200); C. AB PAS histochemical 
stain showed cells without the mucin component (AB PAS x200); D. GCDFP-15 negative stain for apocrine 
differentiation (LSAB x200); E. CKAE1/AE3 showed strong, diffuse positivity (LSAB x200); F. Vimentin stain 
was negative in tumor cells (LSAB x200). 
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Fig. 2 A. GATA3 stain showed strong nuclear positivity in tumor cells (LSAB x 200); B. Strong nuclear positivity of 
ER receptors in all tumor cells (LSAB x200); C. Weak nuclear PR receptor positivity in minority of tumor cells 
(LSAB x200); D. Weak membranous stain of HER2  in minority of tumor cells (LSAB x200); E. Negative 
immunoreactivity for CA125 stain (LSAB x200); F. Negative immunoreactivity for p16 stain (LSAB x200). 
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Invasive lobular carcinoma is the second most com-
mon histologic type of breast carcinoma after ductal in-
vasive carcinoma (NST type in the majority of cases). 
Morphologically, in most cases, this histologic type is 
characterized by infiltration of single-cell file type or dis-
cohesive epithelial cells, which consist of monotonous 
nuclei and inconspicuous nucleoli [11]. In the case of 
metastasing breast cancer confirmation of metastatic dis-
ease and identification of its primary origin is further 
complicated by the existence of multiple (two or more) 
primary malignancies, such as synchronous/ metachro-
nous breast cancer and gynecological malignant tumors 
with an estrogen receptor-positive/cytokeratin 7-positive 
(ER+/CK7+) and mammaglobin-positive immunohisto-
chemical profile. GATA3 expression has been reported 
as a useful marker for differential diagnosis between ma-
lignancies from other localisations and breast carcinomas 
(both primary and metastatic) [6].  
A comparison of hormone receptors and HER2 recep-
tor immunohistochemical expression between primary 
and metastatic breast carcinoma in the liver was also use-
ful in establishing the differential diagnosis. In addition, 
immunohistochemical studies for tissue-specific mark-
ers, such as gross cystic disease fluid protein 15 
(GCDFP-15) and mammaglobin, will be helpful [11]. 
Considering the aforementioned differential diagnoses 
immunohistochemical panel that showed CKAE1/E3, 
GATA3, ER positivity and CA125, GCDFP-15, p16, PR, 
HER2, and vimentin negativity was used. Our data (ER+, 
PR-,HER-2-) matches the result of the study [3] in terms 
that ER+ or PR+/HER-2- (luminal A) subtypes were pre-
dominant in the sites of liver metastases (75.0%).  
In our case, tumor cells were partially hormone- sen-
sitive and HER-2 negative. 
Other factors besides the hormonal (tamoxifen ther-
apy and other causes of hypestrogenism) might be at 
play, such as: HER2- negative status, age, body weight, 
genetic predisposition, etc. 
Conclusion  
This case report highlights a late manifestation of liver 
metastasis from breast cancer, 20 years after the primary 
diagnosis. Considering that our patient had a previous 
history of breast malignancy, clinical suspicion for met-
astatic disease was justified. Also, clinical and radiologi-
cal features may be non-specific, sometimes misleading, 
so the definitive diagnosis represents a challenge for the 
pathologist. 
Late metastasis may be attributed to its hormonal pro-
file which also resulted in the formation of metachronous 
endometrial cancer a year before the liver metastasis. Im-
munohistochemistry was vital for the diagnosis on the 
liver biopsy, in particular GATA3 positivity and vi-
mentin negative staining, which helped us exclude endo-
metrial cancer metastasis. GATA 3(+)/vimentin(-)panel 
proved to be superior to GCDFP-15 and mammaglobin 
in proving the breast origin of  the secondary tumor de-
posit. 
Generally, liver metastasis from breast cancer may 
occur many years after the primary diagnosis,which 
shows the importance and necessity for long -term fol-
low-up of these patients. 
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